Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Obesity and Inflammation: Epidemiology, Risk Factors, and Markers of Inflammation

Heriberto Rodríguez-Hernández, Luis E. Simental-Mendía, Gabriela Rodríguez-Ramírez and 1 more

International Journal of Endocrinology · 2013

doi:10.1155/2013/678159

Abstract

Obesity is a public health problem that has reached epidemic proportions with an increasing worldwide prevalence. The global emergence of obesity increases the risk of developing chronic metabolic disorders. Thus, it is an economic issue that increased the costs of the comorbidities associated. Moreover, in recent years, it has been demonstrated that obesity is associated with chronic systemic inflammation, this status is conditioned by the innate immune system activation in adipose tissue that promotes an increase in the production and release of pro-inflammatory cytokines that contribute to the triggering of the systemic acute-phase response which is characterized by elevation of acute-phase protein levels. On this regard, low-grade chronic inflammation is a characteristic of various chronic diseases such as metabolic syndrome, cardiovascular disease, diabetes, hypertension, non-alcoholic fatty liver disease, and some cancers, among others, which are also characterized by obesity condition. Thus, a growing body of evidence supports the important role that is played by the inflammatory response in obesity condition and the pathogenesis of chronic diseases related.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Epidemiology and Obesity

Obesity is actually an epidemic problem in the world; it has become truly a global problem affecting countries rich and poor. An estimated 500 million adults worldwide are obese and 1.5 billion are overweight or obese. Particularly the prevalence of obesity or combined overweight and obesity has increased in Brazil, Canada, Mexico, and United States. Much of the information about obesity among adults rest in the use of body mass index (BMI) to define obesity, which will be defined as a BMI 30 kg/m2 or greater unless otherwise stated. An examination of national data through 1991 confirmed that significant increases in the United States population had takes place both in adults and children and adolescents. The most recent data from 2005-2006 show that 33.3% of men and 35.3% of women were obese. In Canada, the prevalence of obesity based on measured height and weight has almost doubled in the last two decades and now affects 23% of the adult population.

Obesity is a consequence of many risk factors, as increased energy consumption and reduced physical exercise. Many studies also implicate chronic low grade inflammation in the interplay between obesity and metabolic complications, as many chronic degenerative disorders, including atherosclerosis, and are also commonly associated with hypertension, which itself has also been linked recently to inflammation. Obesity and inflammation have been associated with type 2 diabetes, cardiovascular disease, hypertension, stroke, and gallbladder disease, some forms of cancer, osteoarthritis, and psychosocial problems. In obesity subjects, this problem is commonly associated with other metabolic disorders as hyperglycemia and hypertriglyceridemia, which are well-known risk factors for developing chronic liver disease, as nonalcoholic fatty liver disease (NAFLD). The prevalence of NAFLD reaches 14% to 21%, but is it as high as 90%–95% in obese persons and up to 70% in diabetic patients. Liver inflammation can be induced by the metabolically active intraabdominal fat, and that the high BMI and large waist circumference are significantly associated with the elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Patients with obesity can have elevation of AST and ALT levels, and the reduction of body weight can be achieved with combining diet and physical activity strategies, and reduced levels of aminotransferase. NAFLD and cardiovascular disease have common metabolic risk factors and have 3.7% on mortality; individuals with NAFLD were older, predominantly males, and more likely to be Hispanic. They also had a higher prevalence of all components of metabolic syndrome and cardiovascular disease; however, patients with NAFLD disease did not increase cardiovascular mortality in over 14 years.

For example, within the context of chronic HCV and HBV infection, the presence of cirrhosis is the most important risk factor in the development of hepatocellular carcinoma. There are some nonmodifiable risk factors including older age, male gender, and family history, and several modifiable risk factors in hepatocelular carcinoma, of which the most important are alcohol and tobacco. However, identifying additional modifiable risk factors, including diet, is important, including coffee and tea, fructose, iron, red and with meats, types of fat, selenium, and vitamins D and E.

Diet and life style play a crucial role in the development of some cancers. Actually in Mexico and others countries, more than one-third of cancer deaths can be avoided through dietary modification. Different mechanisms, including antioxidant, anti-inflammatory, and antiestrogenic processes, have been proposed to explain the protective nature of certain dietary components.

2. Obesity and Chronic Inflammation

Inflammation is a physiological response necessary to restore homeostasis altered by diverse stimuli; however, inflammation state chronically established or an excessive response can involve deleterious effects. In overweight and obesity, there exists low-grade chronic inflammation; recent studies have unveiled some of the intracellular pathways of inflammation associated with these conditions; studies in mice and humans evidence that consumption of nutrients may acutely evoke inflammatory responses; so, it is thought that the starting signal of inflammation is overfeeding and the pathway origins in tissues involved in metabolism, that is, adipose tissue, liver, and muscle, which in response of this stimulus triggers the inflammatory response. Compared with lean control, in obese men and women, tissue and liver tissues display an increased activation of kinases such as c-jun N-terminal kinase and the inhibitor of k kinase, which are able to induce the expression of inflammatory cytokines. These kinases regulate downstream transcriptional programs through the transcription factors activator protein-1, nuclear factor κB, and interferon regulatory factor, inducing upregulation of inflammatory mediator gene expression. The increase in cytokines exacerbates receptor activation by establishing a positive feedback loop of inflammation and the inhibitory signaling of metabolic pathways.

Likewise, inflammasome and the Toll-like receptors (TLRs) of the innate immune system are activated as well. Now, strong evidences indicate a prominent role of the inflammasome signaling in the development of a chronic proinflammatory state that impairs insulin sensitivity.

3. The Inflammasome

Inflammasome is a macromolecular innate immune cell sensor that initiates the inflammatory response. Recognition of diverse noxious signals by the inflammasome results in activation of caspase-1, which subsequently induces secretion of potent proinflammatory cytokines, particularly interleukin-1β (IL-1β). In this way, inflammasome-mediated processes are important in regulating metabolic processes.

The inflammasome is a heptamer formed by monomers containing Nod-like receptors (NLRs), the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain), and the enzyme caspase-1. NLRs are characterized by a structure composed of a central domain that mediates nucleotide-binding and oligomerization (NOD or NBS domain), a C-terminal leucine-rich domain (LRR), and a variable N-terminal region required for protein-protein interactions. When assembled as inflammasome, NLR activates caspase-1, which converts pro-IL-1β into active IL-1β.

In the human being, the NLR family consists of 22 members, classified in 4 subfamilies, NLRA, NLRB, NLRC, and NLRP, on basis of their N-terminal domain configuration. They interact with the inflammasome-associated proteins ASC and caspase-1.

A member of the NLRP, named NLRP3, has been linked to metabolic stress, insulin resistance, and type 2 diabetes. NLRP3 inflammasome activation in obesity promotes macrophage-mediated T cell activation in adipose tissue and impairs insulin sensitivity creating a chronic pro-inflammatory state that impairs insulin sensitivity. Inflammasome activation can be induced by hyperglycemia, reactive oxygen species, palmitate, lipopolysaccharides, and uric acid, among other substances. These findings highlight the potential molecular intervention in pathways regulating caspase-1 activation for management of chronic inflammation.

Recent studies show that a protein upregulated by glucose, the thioredoxin interacting protein (TXNIP), interacts with NLRP3, leading to IL-1β secretion and hampering of pancreatic β-cell function.

4. Inflammatory Cytokines

The origin of inflammation during obesity and the underlying molecular mechanisms that explain its occurrence are not yet fully understood, but pro-inflammatory cytokines play a central role. In obesity, there are higher circulating concentrations of inflammatory cytokines than in lean beings, and it is believed that they play a role in causing insulin resistance. The main source of pro-inflammatory cytokines in obesity is the adipose tissue; they are mainly produced by infiltrating macrophages, although adipocytes play a role. In this way, blood concentrations of these cytokines are lowered following weight loss. The main cytokines responsible of chronic inflammation are tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), and the inflammasome-activated IL-1β mentioned earlier.

TNF-α is a pleiotropic molecule that plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism, with numerous effects in adipose tissue, including lipid metabolism and insulin signaling. Circulating TNF-α is increased in obesity and decreased with weight loss. TNF-α promotes the secretion of other powerful pro-inflammatory cytokine, IL-6, and reduces anti-inflammatory cytokines like adiponectin. TNF-α induces adipocytes apoptosis and promotes insulin resistance by the inhibition of the insulin receptor substrate 1 signaling pathway.

IL-6 is a cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 regulates energy homeostasis and inflammation; it is capable of suppressing lipoprotein lipase activity, and it controls appetite and energy intake at hypothalamic level. IL-6 is important in the transition from acute inflammation to chronic inflammatory disease. It contributes to chronic inflammation in conditions such as obesity, insulin resistance, inflammatory bowel disease, inflammatory arthritis, and sepsis when deregulated.

IL-1β is a pyrogenic cytokine. It is mainly produced by blood monocytes in response to infection, injury, or immunologic challenge; it causes fever, hypotension, and production of additional pro-inflammatory cytokines, such as IL-6. IL-1β is formed from its pro-IL-1β inactive precursor by the inflammasome. In this way, IL-1β has now emerged as a prominent instigator of the pro-inflammatory response in obesity.

Important advances have been reached in the last decade in the understanding the role of cytokines and the inflammasome in obesity, chronic inflammation, insulin resistance, and type 2 diabetes. However, further research is required to better understand the underlying mechanisms as they are potential intervention points in the search of new therapeutically modalities for these global health problems.

5. Markers of Inflammation

Several chronic diseases involve an inflammatory response characterized by the increase of cytokines and serum concentrations of acute-phase reactants (markers of active inflammation) such as fibrinogen, C-reactive protein (CRP), complement, serum amyloid A, haptoglobin, sialic acid and low albumin concentrations. Acute-phase reactants are synthesized in the liver, and its production is regulated by cytokines, including IL-6 and TNF-alpha. The CRP, consideredes the classic sensitive acute-phase reactant, is a very sensitive systemic marker of inflammation, and its serum concentration increases rapidly in response to a variety of stimuli. This protein is present in low concentrations under normal conditions.

Visceral adipose tissue may produce inflammatory mediators, which induce the production of acute-phase reactants in hepatocytes and endothelial cells. In fact, because it has been shown that adipocytes express and secrete TNF-alpha, adipose body mass may be an important mediator to explain the relation between obesity and inflammation. Some studies have shown that abdominal adiposity is associated with elevation of CRP levels, independent of body mass index (BMI), which is a measure of general adiposity. The proportion of people with elevated hs-CRP was significantly higher in those individuals with abdominal adiposity than control subjects, although they had a similar BMI. IL-6 is a pro-inflammatory cytokine synthesized by adipose tissue, endothelial cells, macrophages, and lymphocytes. The CRP is synthesized in the liver largely in response to IL-6 stimuli. Individuals with obesity are at increased risk for various chronic diseases, several of which are also characterized by elevated CRP concentrations. Because adipose tissue is a major source of pro-inflammatory cytokines such as IL-6 and TNF-alpha, both cytokines increase hepatic lipogenesis and trigger a systemic acute-phase response.

In recent years, it has been demonstrated that obesity is associated with low-grade inflammatory process characterized by the increase in circulating levels of pro-inflammatory cytokines such as IL-6, TNF-alpha, and acute-phase proteins (CRP and haptoglobin) in healthy obese subjects. This phenomenon is also observed in obese children who have higher CRP levels than normal weight children. Some studies have reported that weight loss, through diet, is associated with reduction in circulating levels of IL-6, TNF-alpha, CRP, and other markers of inflammation, independently of age, sex, and BMI. Similarly, weight reduction observed in subjects after gastric bypass shows decrease of CRP and IL-6 levels.

6. Metabolic Syndrome

The metabolic syndrome is characterized as the presence of three or more of the following features: obesity, hyperglycemia, hypertension, low HDL cholesterol levels, and/or hypertriglyceridemia. Although pathogenic mechanisms are poorly understood, a central role has been attributed to the pro-inflammatory cytokines TNF-alpha and IL-6, since both are synthesized by adipose tissue. This syndrome has been associated with markers of inflammatory activity, such as CRP, IL-6, serum amyloid A, and soluble adhesion molecules.

Risk Factors. Low-grade chronic inflammation is associated with metabolic syndrome and some features of insulin resistance. Other studies have demonstrated significant correlation between CRP levels with features of the metabolic syndrome, including adiposity, hyperinsulinemia, insulin resistance, hypertriglyceridemia, and low HDL cholesterol. Few studies have reported the association between CRP and development of metabolic syndrome. In addition, it has been observed that elevated hs-CRP levels are associated with increased risk for incident cardiovascular events among individuals as having the metabolic syndrome. Inflammation has been proposed as common part of different metabolic disturbances of insulin, glucose, and lipids that influence the underlying development of metabolic syndrome.

Also, it has shown that CRP adds independent prognostic information on severity of metabolic syndrome. Given the evidence, it has been proposed that CRP is an additional component of metabolic syndrome. In one study, it was reported that elevated levels of CRP (≥3 mg/L) may increase the risk of metabolic syndrome mediated through obesity and factors related to insulin resistance.

Treatment. Observational studies have shown that dietary patterns similar to the Mediterranean diet, rich in fruit and vegetables and high in monounsaturated fats and fiber, resulted in decrease prevalence of the metabolic syndrome. In addition, interventional studies also demonstrated a decrease in markers of inflammation in subjects with metabolic syndrome consuming Mediterranean diet and/or national dietary guidelines.

Studies that evaluate markers of inflammation in individuals with metabolic syndrome are scarce; however, some have shown anti-inflammatory effects of statin therapy. Because subjects with metabolic syndrome exhibit increased inflammation, after therapeutic lifestyle changes, statins could be a therapeutic option.

7. Cardiovascular Disease

In the last years, different markers of inflammation (such as CRP, IL-6, and TNF-alpha, among others) have been studied in prediction of coronary events; on this regard, CRP is the most important marker for cardiovascular disease.

Risk Factors. Circulating elevated levels of inflammatory markers, such as CRP, TNF-alpha, and IL-6, are associated with increased risk of developing cardiovascular disease; even some acute-phase reactants may also contribute to their pathogenesis. Though in mild degree, chronic elevation of CRP levels, even within normal value range, is an independent predictor of future cardiovascular events. Stratified ranges of high-sensitivity CRP levels of <1, 1–3, and >3 mg/L correspond to low, moderate, and high risks for future cardiovascular events. Previously, some studies have found a significative association between CRP and cardiovascular risk. This finding was observed for the first time over 50 years ago, where increased CRP level, after myocardial infarction, was identified as marker of poor prognostic. Later, the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group reported that CRP concentrations were higher in the patients who had coronary events than in those without such events. In addition, the Cholesterol and Recurrent Events Trial showed that elevated CRP levels are associated with major risk of coronary events after myocardial infarction. A growing body of evidence has corroborated that inflammation is a strong predictor of future cardiovascular events.

Furthermore, hsCRP is better marker of cardiovascular disease than others acute-phase reactants, cytokines, and soluble adhesion molecules. Thus, supported by a large number of observational studies and meta-analyses, CRP is considered as a mediator of cardiovascular disease, independently of age, smoking, cholesterol levels, blood pressure, and diabetes among others traditional risk factors evaluated in the clinical setting. Thus, CRP is one of the most well-documented emerging cardiovascular disease risk factors.

Treatment. Some interventional studies using Mediterranean diet and others characterized by increased intake of mustard or soybean oil, fruits, vegetables, nuts, and whole grains reduced the rate of cardiovascular disease with significant anti-inflammatory effect. Also, various observational and interventional studies found that intake of omega-3 and omega-6 fatty acids and alpha-linolenic acid resulted in lower risk of cardiovascular disease and lower concentrations of markers of inflammation. Moreover, several studies have shown that statin therapy is associated with reduced inflammation and cardiovascular risk reduction.

8. Diabetes

Several studies have shown that subclinical systemic inflammation, as measured by elevated levels of CRP and IL-6, predicts the development of diabetes. In fact, IL-6 may interfere with insulin signalling through induction of proteins that bind to the insulin receptor. On this regard, a growing body of evidence supports the hypothesis that chronic systemic inflammation contributes to decrease of insulin sensitivity at peripheral tissues.

Risk Factors. Several studies in healthy subjects have confirmed that elevated levels of CRP and cytokines IL-6 and TNF-alpha are associated with insulin resistance. In addition, it has been shown that in the individuals with impaired glucose tolerance, the low-grade chronic inflammation is related to glucose metabolic disturbances.

It has been reported that TNF-alpha is overexpressed in the adipose and muscle tissues of obese and insulin-resistant nondiabetic subjects, overexpression that is positively correlated with insulin resistance. Interestingly, circulating TNF-alpha levels are higher in type 2 diabetes as compared with IFG/IGT. In addition, several cross-sectional studies have shown an increase of CRP levels in patients with diabetes and the increase of CRP, IL-6, and TNF-alpha in subjects with IGT.

Moreover, in obesity there are elevated levels of several kinases such as protein kinase C isoforms, I Kappa B Kinase-β, and c-jun-terminal kinase, and these kinases have been implicated in alteration of insulin signaling by promoting serine phosphorylation of insulin receptor substrate which is associated with suppression of tyrosine phosphorylation of this substrate. Also, various studies have demonstrated that nutrient excess and obesity are associated with elevated levels of free fatty acids, which can induce both insulin resistance in peripheral tissues and activation of innate immunity.

Furthermore, it is difficult to set cut-point values to predict risk of development disease because intermediate values of CRP are at moderate risk for metabolic disturbances. However, it has been reported that patients with diabetes and CRP values >3 mg/L have 51% higher risk of all-cause mortality and 44% higher risk of cardiovascular mortality than subjects with diabetes and CRP <3 mg/L of similar age and sex, independently of classical risk factors such as lipids, blood pressure, and glycemia.

Treatment. In clinical field, there are different therapeutic options, such as genetic, biochemical, and pharmacological targeting of inflammatory signalling pathways improving insulin action, a central problem in the pathophysiology of type 2 diabetes. Existing evidence about inhibiting specific inflammatory kinases pathway improves insulin action in animal models. Pharmacological therapeutics using thiazolidinediones exhibited anti-inflammatory effects inhibiting both adipocyte and macrophage function in obesity and type 2 diabetes. Various clinical studies, using anti-inflammatory drugs to treat type 2 diabetes and even prediabetes, showed improvements in beta-cell function and insulin sensitivity, reducing glucose levels. In addition, others studies in patients with type 2 diabetes taking statins have demonstrated a beneficial and additive effect on markers of inflammation, which could be an alternative therapeutic for this disease; however, the clinical practice recommendations should be considered about the appropriate use of statin therapy because basic studies have documented controversial results regarding the beneficial and adverse effects on insulin secretion and sensitivity.

9. Conclusion

The origin of inflammation during obesity and the underlying molecular mechanisms that explain its occurrence are not still fully understood, but pro-inflammatory cytokines play a central role. In obesity, there are higher circulating concentrations of inflammatory cytokines than in lean beings, and it is believed that they play a role in causing insulin resistance. The main source of proinflammatory cytokines in obesity is the adipose tissue; they are mainly produced by infiltrating macrophages, although adipocytes play a role. Obesity is a consequence of many risk factors, as increased energy consumption and reduced physical exercise. Many problems ecist in patients with obesity, as cardiovascular disease, diabetes, metabolic syndrome, and NAFLD, among others, predicting the risk of future cardiovascular events and mortality. Different mechanisms, including antioxidant, anti-inflammatory, fiber diet, and antiestrogenic processes, have been proposed to explain the protective nature of certain dietary components, particularly, components of Mediterranean diet which could be an important therapeutic lifestyle change which allows to avoid the development of metabolic diseases.

References 187

  1. 1.

    Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. The Lancet. 2011;377(9765):557-567.

    Not in our library10.1016/s0140-6736(10)62037-5

  2. 2.

    Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. The Journal of Clinical Endocrinology and Metabolism. 2008;93:S1-S8.

    Not in our library10.1210/jc.2008-1356

  3. 3.

    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 1998.

    Not in our library

  4. 4.

    Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. Journal of the American Medical Association. 1994;272(3):205-211.

    Not in our library10.1001/jama.272.3.205

  5. 5.

    Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL. Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Surveys, 1963 to 1991. Archives of Pediatrics and Adolescent Medicine. 1995;149(10):1085-1091.

    Not in our library10.1001/archpedi.1995.02170230039005

  6. 6.

    Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. Journal of the American Medical Association. 2002;288(14):1758-1761.

    Not in our library10.1001/jama.288.14.1758

  7. 7.

    Orpana HM, Berthelot JM, Kaplan MS, Feeny DH, McFarland B, Ross NA. BMI and mortality: results from a national longitudinal study of canadian adults. Obesity. 2009;18(1):214-218.

    Not in our library10.1038/oby.2009.191

  8. 8.

    Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.

    Not in our library10.1038/nature05485

  9. 9.

    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731-733.

    Not in our library10.1161/01.cir.98.8.731

  10. 10.

    Kaplan MS, Huguet N, Newsom JT, McFarland BH, Lindsay J. Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey. Journals of Gerontology A. 2003;58(11):1018-1030.

    Not in our library10.1093/gerona/58.11.m1018

  11. 11.

    Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113-121.

    Not in our library10.1053/j.gastro.2005.04.014

  12. 12.

    Angulo P. Medical progress: nonalcoholic fatty liver disease. The New England Journal of Medicine. 2002;346(16):1221-1231.

    Not in our library10.1056/nejmra011775

  13. 13.

    Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology. 2009;8(supplement 1):S4-S8.

    Not in our library

  14. 14.

    Ruhl CE, Everhart JE. Trunk fat is associated with increased serum levels of alanine aminotransferase in the United States. Gastroenterology. 2010;138(4):1346.e3-1356.e3.

    Not in our library10.1053/j.gastro.2009.12.053

  15. 15.

    Rodriguez-Hernandez H, Cervantes-Alvarez M, Rodriguez- Moran M, Guerrero-Romero F. Decrease of aminotransferase levels in obese women is related to body weight reduction, irrespective of type of diet. Annals of Hepatology. 2011;10:486-492.

    Not in our library

  16. 16.

    Rodriguez-Hernandez H, Morales-Amaya UA, Rosales-Valdéz R, Rivera-Hinojosa F, Rodriguez-Moran M, Guerrero-Romero F. Adding cognitive behavioural treatment to either low-carbohydrate or low-fat diets: differential short-term effects. British Journal of Nutrition. 2009;102(12):1847-1853.

    Not in our library10.1017/s0007114509991231

  17. 17.

    Stepanova M, Younoussi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in US population. Clinical Gastroenterology and Hepatology. 2012;10:646-650.

    Not in our library10.1016/j.cgh.2011.12.039

  18. 18.

    Kuper H, Tzonou A, Kakalamani E. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocelular carcinoma. International Journal of Cancer. 2000;85:498-502.

    Not in our library

  19. 19.

    Trichopoulos D, Bamia C, Lagiou P. Hepatocelular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. Journal of the National Cancer Institute. 2011;103:1686-1695.

    Not in our library10.1093/jnci/djr395

  20. 20.

    Freedman ND, Marrero JA. Can dietary fish intake prevent liver cancer? Gastroenterology. 2012;142:1411-1413.

    Not in our library10.1053/j.gastro.2012.04.038

  21. 21.

    Su LJ, Mahabir S, Ellison GL, McGuinn LA, Reid BC. Epigenetic contributions to the relationship between cancer and dietary intake of nutrients, bioactive food, components, and environmental toxicants. Nutrigenomics. 2012;2:1-12.

    Not in our library10.3389/fgene.2011.00091

  22. 22.

    Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annual Review of Immunology. 2011;29:415-445.

    Not in our library10.1146/annurev-immunol-031210-101322

  23. 23.
    Inflammation as a Link between Obesity and Metabolic Syndrome · 2012
    No notice
  24. 24.

    Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the danger zone. Cell Metabolism. 2012;15:10-18.

    Not in our library10.1016/j.cmet.2011.10.011

  25. 25.

    Solinas G, Karin M. JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction. The FASEB Journal. 2010;24(8):2596-2611.

    Not in our library10.1096/fj.09-151340

  26. 26.

    Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. American Journal of Physiology. 2009;296(4):E581-E591.

    Not in our library10.1152/ajpendo.90437.2008

  27. 27.

    Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. 2010;327(5963):296-300.

    Not in our library10.1126/science.1184003

  28. 28.

    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. The Journal of Clinical Investigation. 2006;116(11):3015-3025.

    Not in our library10.1172/jci28898

  29. 29.

    Lamkanfi M, Kanneganti TD. The inflammasome: a remote control for metabolic syndrome. Cell Research. 2012;22:1095-1098.

    Not in our library10.1038/cr.2012.55

  30. 30.

    Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1β in inflammatory disorders. Nature Clinical Practice Rheumatology. 2008;4(1):34-42.

    Not in our library10.1038/ncprheum0681

  31. 31.

    Dagenais M, Dupaul-Chicoine J, Saleh M. Function of NOD-like receptors in immunity and disease. Current Opinion in Investigational Drugs. 2010;11(11):1246-1255.

    Not in our library

  32. 32.

    Dagenais M, Skeldon A, Saleh M. The inflammasome: in memory of Dr. Jurg Tschopp. Cell Death and Differentiation. 2012;19:5-12.

    Not in our library10.1038/cdd.2011.159

  33. 33.

    Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Cell Death and Differentiation. 2011;17:179-188.

    Not in our library10.1038/nm.2279

  34. 34.

    Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine. 2007;356(15):1517-1526.

    Not in our library10.1056/nejmoa065213

  35. 35.

    Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology. 2010;11(2):136-140.

    Not in our library10.1038/ni.1831

  36. 36.

    Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 1996;271(5249):665-668.

    Not in our library10.1126/science.271.5249.665

  37. 37.

    Wang B, Trayhurn P. Acute and prolonged effects of TNF-α on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Archiv European Journal of Physiology. 2006;452(4):418-427.

    Not in our library10.1007/s00424-006-0055-8

  38. 38.

    Stenlöf K, Wernstedt I, Fjällman T, Wallenius V, Wallenius K, Jansson JO. Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. Journal of Clinical Endocrinology and Metabolism. 2003;88(9):4379-4383.

    Not in our library10.1210/jc.2002-021733

  39. 39.

    Naugler WE, Karin M. The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends in Molecular Medicine. 2008;14(3):109-119.

    Not in our library10.1016/j.molmed.2007.12.007

  40. 40.

    Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-823.

    Not in our library10.2337/diacare.27.3.813

  41. 41.

    Baumann H, Gauldie J. The acute phase response. Immunology Today. 1994;15(2):74-80.

    Not in our library10.1016/0167-5699(94)90137-6

  42. 42.

    Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. The New England Journal of Medicine. 1999;340(6):448-454.

    Not in our library10.1056/nejm199902113400607

  43. 43.

    Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148(2):209-214.

    Not in our library10.1016/s0021-9150(99)00463-3

  44. 44.

    Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. International Journal of Obesity. 2003;27(supplement 3):S25-S28.

    Not in our library10.1038/sj.ijo.0802496

  45. 45.

    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation. 2003;107(3):499-511.

    Not in our library10.1161/01.cir.0000052939.59093.45

  46. 46.

    Pepys MB, Hirschfield GM. C-reactive protein: a critical update. The Journal of Clinical Investigation. 2003;111(12):1805-1812.

    Not in our library10.1172/jci18921

  47. 47.

    Jacobs M, van Greevenbroek MMJ, van der Kallen CJH, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. European Journal of Clinical Investigation. 2009;39(6):437-444.

    Not in our library10.1111/j.1365-2362.2009.02129.x

  48. 48.

    Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. The Journal of Clinical Investigation. 1995;95(5):2111-2119.

    Not in our library10.1172/jci117899

  49. 49.

    Lapice E, Maione S, Patti L, et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care. 2009;32(9):1734-1736.

    Not in our library10.2337/dc09-0176

  50. 50.

    Laaksonen DE, Niskanen L, Nyyssönen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia. 2004;47(8):1402-1410.

    Not in our library10.1007/s00125-004-1472-x

  51. 51.

    Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41(supplement 2):97-101.

    Not in our library10.2337/diab.41.2.s97

  52. 52.

    Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 1994;43(11):1271-1278.

    Not in our library10.2337/diab.43.11.1271

  53. 53.

    Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obesity Research. 2002;10(supplement 10):97S-104S.

    Not in our library10.1038/oby.2002.202

  54. 54.

    Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obesity Research. 2003;11(11):1278-1289.

    Not in our library10.1038/oby.2003.174

  55. 55.

    Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research. 2005;96(9):939-949.

    Not in our library10.1161/01.res.0000163635.62927.34

  56. 56.

    Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. American Journal of Physiology. 2005;288(5):H2031-H2041.

    Not in our library10.1152/ajpheart.01058.2004

  57. 57.

    Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics. 2001;107(1):1-6.

    Not in our library10.1542/peds.107.1.e13

  58. 58.

    Nicoletti G, Giugliano G, Pontillo A, et al. Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. Journal of Endocrinological Investigation. 2003;26(3):RC5-RC8.

    Not in our library10.1007/bf03345154

  59. 59.

    Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21(6):968-970.

    Not in our library10.1161/01.atv.21.6.968

  60. 60.

    Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23(6):1042-1047.

    Not in our library10.1161/01.atv.0000073313.16135.21

  61. 61.

    Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.

    Not in our library10.2337/diab.37.12.1595

  62. 62.

    Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia. 1991;34(6):416-422.

    Not in our library10.1007/bf00403180

  63. 63.

    Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ. Risk factor clustering in the insulin resistance syndrome. The strong heart study. American Journal of Epidemiology. 1998;148(9):869-878.

    Not in our library10.1093/oxfordjournals.aje.a009712

  64. 64.

    Carantoni M, Zuliani G, Volpato S, et al. Relationships between fasting plasma insulin, anthropometrics, and metabolic parameters in a very old healthy population. Metabolism. 1998;47(5):535-540.

    Not in our library10.1016/s0026-0495(98)90236-0

  65. 65.

    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91.

    Not in our library10.1126/science.7678183

  66. 66.

    Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. Journal of Clinical Endocrinology and Metabolism. 1997;82(12):4196-4200.

    Not in our library10.1210/jcem.82.12.4450

  67. 67.

    Anty R, Bekri S, Luciani N, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. American Journal of Gastroenterology. 2006;101(8):1824-1833.

    Not in our library10.1111/j.1572-0241.2006.00724.x

  68. 68.

    Calabro P, Chang DW, Willerson JT, Yeh ETH. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. Journal of the American College of Cardiology. 2005;46(6):1112-1113.

    Not in our library10.1016/j.jacc.2005.06.017

  69. 69.

    Florez H, Castillo-Florez S, Mendez A, et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Research and Clinical Practice. 2006;71(1):92-100.

    Not in our library10.1016/j.diabres.2005.05.003

  70. 70.

    González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. European Journal of Clinical Nutrition. 2006;60(6):802-809.

    Not in our library10.1038/sj.ejcn.1602384

  71. 71.

    Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-674.

    Not in our library10.1161/01.cir.0000055188.83694.b3

  72. 72.

    van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14(12):2127-2131.

    Not in our library10.1038/oby.2006.248

  73. 73.

    Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. European Journal of Clinical Investigation. 2008;38(7):502-509.

    Not in our library10.1111/j.1365-2362.2008.01962.x

  74. 74.

    Matsuo Y, Hashizume T, Shioji S, Akasaka T. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease. Circulation Journal. 2008;72(12):2046-2050.

    Not in our library10.1253/circj.cj-08-0337

  75. 75.

    Kressel G, Trunz B, Bub A, et al. Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk. Atherosclerosis. 2009;202(1):263-271.

    Not in our library10.1016/j.atherosclerosis.2008.04.012

  76. 76.

    Bataille R, Klein B, Kushner I. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis and Rheumatism. 1992;35(8):982-984.

    Not in our library10.1002/art.1780350824

  77. 77.

    Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochemical Journal. 1990;265(3):621-636.

    Not in our library10.1042/bj2650621

  78. 78.

    Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Letters. 1989;242(2):237-239.

    Not in our library10.1016/0014-5793(89)80476-4

  79. 79.

    Castell JV, Gomes-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Letters. 1988;232(2):347-350.

    Not in our library10.1016/0014-5793(88)80766-x

  80. 80.

    Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. Journal of the American College of Cardiology. 2005;46(11):1978-1985.

    Not in our library10.1016/j.jacc.2005.06.082

  81. 81.

    Haught WH, Mansour M, Rothlein R, et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. American Heart Journal. 1996;132(1 I):1-8.

    Not in our library10.1016/s0002-8703(96)90383-x

  82. 82.

    Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. European Journal of Endocrinology. 2003;149(6):601-608.

    Not in our library10.1530/eje.0.1490601

  83. 83.

    Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews. 2003;24(3):278-301.

    Not in our library10.1210/er.2002-0010

  84. 84.

    Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(4):972-978.

    Not in our library10.1161/01.atv.19.4.972

  85. 85.

    Festa A, D’Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000;101(1):42-47.

    Not in our library10.1161/01.cir.102.1.42

  86. 86.

    Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City diabetes study. Diabetes Care. 2002;25(11):2016-2021.

    Not in our library10.2337/diacare.25.11.2016

  87. 87.

    Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):391-397.

    Not in our library10.1161/01.cir.0000055014.62083.05

  88. 88.

    Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108(4):414-419.

    Not in our library10.1161/01.cir.0000080897.52664.94

  89. 89.

    Williams DEM, Prevost AT, Whichelow MJ, Cox BD, Day NE, Wareham NJ. A cross-sectional study of dietary patterns with glucose intolerance and other features of the metabolic syndrome. British Journal of Nutrition. 2000;83(3):257-266.

    Not in our library10.1017/s0007114500000337

  90. 90.

    McKeown NM, Meigs JB, Liu S, Saltzman E, Wilson PWF, Jacques PF. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care. 2004;27(2):538-546.

    Not in our library10.2337/diacare.27.2.538

  91. 91.

    Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. American Heart Journal. 2004;147(1):106-112.

    Not in our library10.1016/s0002-8703(03)00442-3

  92. 92.

    Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Journal of the American Medical Association. 2004;292(12):1440-1446.

    Not in our library10.1001/jama.292.12.1440

  93. 93.

    Ahluwalia N, Andreeva VA, Kesse-Guyot E, Hercberg S. Dietary patterns, inflammation and the metabolic syndrome. Diabetes & Metabolism. 2012.

    Not in our library10.1016/j.diabet.2012.08.007

  94. 94.

    Lazich I, Sarafidis P, de Guzman E, Patel A, Oliva R, Bakris G. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes, Obesity and Metabolism. 2012;14(2):181-186.

    Not in our library10.1111/j.1463-1326.2011.01510.x

  95. 95.

    Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism. 2006;91(11):4489-4496.

    Not in our library10.1210/jc.2006-0299

  96. 96.

    Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine. 2002;347(20):1557-1565.

    Not in our library10.1056/nejmoa021993

  97. 97.

    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. The New England Journal of Medicine. 1997;336(14):973-979.

    Not in our library10.1056/nejm199704033361401

  98. 98.

    Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17(6):1121-1127.

    Not in our library10.1161/01.atv.17.6.1121

  99. 99.

    Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation. 1999;99(2):237-242.

    Not in our library10.1161/01.cir.99.2.237

  100. 100.

    Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC Study. Circulation. 2003;108(19):2317-2322.

    Not in our library10.1161/01.cir.0000097109.90783.fc

  101. 101.

    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772.

    Not in our library10.1161/01.cir.101.15.1767

  102. 102.

    Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149-2153.

    Not in our library10.1161/01.cir.101.18.2149

  103. 103.

    Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. American Journal of Physiology. 2005;288(5):H2031-H2041.

    Not in our library10.1152/ajpheart.01058.2004

  104. 104.

    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. The New England Journal of Medicine. 2000;342(12):836-843.

    Not in our library10.1056/nejm200003233421202

  105. 105.

    Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP. The relation between serum albumin levels and risk of coronary heart disease in the multiple risk factor intervention trial. American Journal of Epidemiology. 1991;134(11):1266-1277.

    Not in our library10.1093/oxfordjournals.aje.a116030

  106. 106.

    Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. The New England Journal of Medicine. 1994;331(7):417-424.

    Not in our library10.1056/nejm199408183310701

  107. 107.

    Thompson SG, Kienast J, Pyke SDM, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. The New England Journal of Medicine. 1995;332(10):635-641.

    Not in our library10.1056/nejm199503093321003

  108. 108.

    Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98(9):839-844.

    Not in our library10.1161/01.cir.98.9.839

  109. 109.

    Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007-2011.

    Not in our library10.1161/01.cir.97.20.2007

  110. 110.

    Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. British Medical Journal. 2000;321(7255):199-204.

    Not in our library10.1136/bmj.321.7255.199

  111. 111.

    Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105(22):2595-2599.

    Not in our library10.1161/01.cir.0000017493.03108.1c

  112. 112.

    Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. American Journal of Epidemiology. 1996;144(6):537-547.

    Not in our library10.1093/oxfordjournals.aje.a008963

  113. 113.

    Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. European Heart Journal. 2000;21(19):1584-1590.

    Not in our library10.1053/euhj.1999.1982

  114. 114.

    Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine. 1999;106(5):506-512.

    Not in our library10.1016/s0002-9343(99)00066-2

  115. 115.

    Roberts WL. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: laboratory tests available to asses inflammation-performance and standardization: a background paper. Circulation. 2004;110(25):e572-e576.

    Not in our library10.1161/01.cir.0000148986.52696.07

  116. 116.

    Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ESG, Kastelein JJP. C-reactive protein is a mediator of cardiovascular disease. European Heart Journal. 2010;31(17):2087-2091.

    Not in our library10.1093/eurheartj/ehq238

  117. 117.

    Wilson PW, Pencina M, Jacques P, Selhub J, D’Agostino R, O’Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circulation. 2008;1(2):92-97.

    Not in our library10.1161/circoutcomes.108.831198

  118. 118.

    Keavney B. C reactive protein and the risk of cardiovascular disease. British Medical Journal. 2011;342, article d144.

    Not in our library10.1136/bmj.d144

  119. 119.

    Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the population science discussion group. Circulation. 2004;110(25):e554-e559.

    Not in our library10.1161/01.cir.0000148982.95775.bf

  120. 120.

    de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779-785.

    Not in our library10.1161/01.cir.99.6.779

  121. 121.

    Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. The Lancet. 2002;360(9344):1455-1461.

    Not in our library10.1016/s0140-6736(02)11472-3

  122. 122.

    Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108(2):155-160.

    Not in our library10.1161/01.cir.0000079224.46084.c2

  123. 123.

    Djoussé L, Pankow JS, Eckfeldt JH, et al. Relation between dietary linolenic acid and coronary artery disease in the National Heart, Lung, and Blood Institute Family Heart study. American Journal of Clinical Nutrition. 2001;74(5):612-619.

    Not in our library10.1093/ajcn/74.5.612

  124. 124.

    Lopez-Garcia E, Schulze MB, Manson JE, et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. Journal of Nutrition. 2004;134(7):1806-1811.

    Not in our library10.1093/jn/134.7.1806

  125. 125.

    Madsen T, Skou HA, Hansen VE, et al. C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. American Journal of Cardiology. 2001;88(10):1139-1142.

    Not in our library10.1016/s0002-9149(01)02049-5

  126. 126.

    Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM. Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. Journal of Nutrition. 2004;134(11):2991-2997.

    Not in our library10.1093/jn/134.11.2991

  127. 127.

    Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A. Dietary α-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis. 2003;167(2):237-242.

    Not in our library10.1016/s0021-9150(02)00427-6

  128. 128.

    Bemelmans WJE, Lefrandt JD, Feskens EJM, et al. Increased α-linolenic acid intake lowers C-reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition. 2004;58(7):1083-1089.

    Not in our library10.1038/sj.ejcn.1601938

  129. 129.

    Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008;359(21):2195-2207.

    Not in our library10.1056/nejmoa0807646

  130. 130.

    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The New England Journal of Medicine. 1995;333(20):1301-1307.

    Not in our library10.1056/nejm199511163332001

  131. 131.

    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Journal of the American Medical Association. 1998;279(20):1615-1622.

    Not in our library10.1001/jama.279.20.1615

  132. 132.

    Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. The New England Journal of Medicine. 2005;352(1):20-28.

    Not in our library10.1056/nejmoa042378

  133. 133.

    Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281-288.

    Not in our library10.1161/circulationaha.106.628909

  134. 134.

    Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England Journal of Medicine. 2005;352(1):29-38.

    Not in our library10.1056/nejmoa042000

  135. 135.

    Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet. 2009;373(9670):1175-1182.

    Not in our library10.1016/s0140-6736(09)60447-5

  136. 136.

    Liao JK. Role of statin pleiotropism in acute coronary syndromes and stroke. International Journal of Clinical Practice, Supplement. 2003;(134):51-57.

    Not in our library

  137. 137.

    Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. Journal of the American Medical Association. 1998;279(20):1643-1650.

    Not in our library10.1001/jama.279.20.1643

  138. 138.

    Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coronary Artery Disease. 2003;14(4):329-334.

    Not in our library10.1097/01.mca.0000078062.22445.60

  139. 139.

    Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. International Journal of Cardiology. 2001;77(2-3):247-253.

    Not in our library10.1016/s0167-5273(00)00439-3

  140. 140.

    Wæhre T, Damås JK, Gullestad L, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. Journal of the American College of Cardiology. 2003;41(9):1460-1467.

    Not in our library10.1016/s0735-1097(03)00263-8

  141. 141.

    Wæhre T, Yndestad A, Smith C, et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors. Circulation. 2004;109(16):1966-1972.

    Not in our library10.1161/01.cir.0000125700.33637.b1

  142. 142.

    Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 2001;286(3):327-334.

    Not in our library10.1001/jama.286.3.327

  143. 143.

    Festa A, D’Agostino R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131-1137.

    Not in our library10.2337/diabetes.51.4.1131

  144. 144.

    Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003;26(10):2754-2757.

    Not in our library10.2337/diacare.26.10.2754

  145. 145.

    Tan KCB, Wat NMS, Tam SCF, Janus ED, Lam TH, Lam KSL. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care. 2003;26(8):2323-2328.

    Not in our library10.2337/diacare.26.8.2323

  146. 146.

    Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg Cohort Study, 1984–1998. Archives of Internal Medicine. 2003;163(1):93-99.

    Not in our library10.1001/archinte.163.1.93

  147. 147.

    Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50(10):2384-2389.

    Not in our library10.2337/diabetes.50.10.2384

  148. 148.

    Freeman DJ, Norrie J, Caslake MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study. Diabetes. 2002;51(5):1596-1600.

    Not in our library10.2337/diabetes.51.5.1596

  149. 149.

    Snijder MB, Dekker JM, Visser M, et al. C-reactive protein and diabetes mellitus type 2. Diabetologia. 2001;44(Supplement 1, article 115A).

    Not in our library

  150. 150.

    Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. The Journal of Biological Chemistry. 2003;278(16):13740-13746.

    Not in our library10.1074/jbc.m210689200

  151. 151.

    Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41(10):1241-1248.

    Not in our library10.1007/s001250051058

  152. 152.

    Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation. 1999;100(1):96-102.

    Not in our library10.1161/01.cir.100.1.96

  153. 153.

    Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology. 2000;152(10):897-907.

    Not in our library10.1093/aje/152.10.897

  154. 154.

    Hak AE, Pols HAP, Stehouwer CDA, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study. Journal of Clinical Endocrinology and Metabolism. 2001;86(9):4398-4405.

    Not in our library10.1210/jcem.86.9.7873

  155. 155.

    Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism. 2002;51(6):743-749.

    Not in our library10.1053/meta.2002.32804

  156. 156.

    Müller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia. 2002;45(6):805-812.

    Not in our library10.1007/s00125-002-0829-2

  157. 157.

    Temelkova-Kurktschiev T. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia. 2002;45(1, article 151).

    Not in our library10.1007/s125-002-8256-1

  158. 158.

    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995;95(5):2409-2415.

    Not in our library10.1172/jci117936

  159. 159.

    Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFα by human muscle: relationship to insulin resistance. The Journal of Clinical Investigation. 1996;97(4):1111-1116.

    Not in our library10.1172/jci118504

  160. 160.

    Peraldi P, Spiegelman B. TNF-α and insulin resistance: summary and future prospects. Molecular and Cellular Biochemistry. 1998;182(1-2):169-175.

    Not in our library

  161. 161.

    Katsuki A, Sumida Y, Murashima S, et al. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 1998;83(3):859-862.

    Not in our library10.1210/jcem.83.3.4618

  162. 162.

    Winkler G, Salamon F, Salamon D, Speer G, Simon K, Cseh K. Elevated serum tumour necrosis factor. alpha levels can contribute to the insulin resistance in Type II (non-insulin-dependent) diabetes and in obesity. Diabetologia. 1998;41(7):860-862.

    Not in our library10.1007/s001250051000

  163. 163.

    Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sciences. 2000;67(3):291-300.

    Not in our library10.1016/s0024-3205(00)00622-6

  164. 164.

    Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(2):455-461.

    Not in our library10.2337/diabetes.51.2.455

  165. 165.

    Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today. 1994;15(2):81-87.

    Not in our library10.1016/0167-5699(94)90138-4

  166. 166.

    Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle. 2007;6(8):888-894.

    Not in our library10.4161/cc.6.8.4135

  167. 167.

    Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKβ. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(5):989-994.

    Not in our library10.1161/01.atv.0000160549.60980.a8

  168. 168.

    Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of Clinical Investigation. 1996;97(12):2859-2865.

    Not in our library10.1172/jci118742

  169. 169.

    Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. International Journal of Obesity and Related Metabolic Disorders. 2003;27(Supplement 3):S49-S52.

    Not in our library10.1038/sj.ijo.0802501

  170. 170.

    Hotamisligil GS. Inflammatory pathways and insulin action. International Journal of Obesity. 2003;27(3):S53-S55.

    Not in our library10.1038/sj.ijo.0802502

  171. 171.

    Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nature Medicine. 2005;11(2):183-190.

    Not in our library10.1038/nm1166

  172. 172.

    Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. The Journal of Clinical Investigation. 2006;116(7):1793-1801.

    Not in our library10.1172/jci29069

  173. 173.

    Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the casale monferrato study. Diabetes. 2009;58(4):926-933.

    Not in our library10.2337/db08-0900

  174. 174.

    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. The Journal of Clinical Investigation. 2005;115(5):1111-1119.

    Not in our library10.1172/jci25102

  175. 175.

    Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nature Medicine. 2004;10(10):1128-1132.

    Not in our library10.1038/nm1111

  176. 176.

    Liu G, Rondinone CM. JNK: bridging the insulin signaling and inflammatory pathway. Current Opinion in Investigational Drugs. 2005;6(10):979-987.

    Not in our library

  177. 177.

    Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metabolism. 2005;1(2):107-119.

    Not in our library10.1016/j.cmet.2004.12.008

  178. 178.

    Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. The Journal of Clinical Investigation. 2002;109(10):1321-1326.

    Not in our library10.1172/jci14955

  179. 179.

    Goldfine AB, Silver R, Aldhahi W, et al. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and Translational Science. 2008;1(1):36-43.

    Not in our library10.1111/j.1752-8062.2008.00026.x

  180. 180.

    Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Annals of Internal Medicine. 2010;152(6):346-357.

    Not in our library10.1059/0003-4819-152-6-201003160-00004

  181. 181.

    Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289-294.

    Not in our library10.2337/dc07-1338

  182. 182.

    Koska J, Ortega E, Bunt JC, et al. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia. 2009;52(3):385-393.

    Not in our library10.1007/s00125-008-1239-x

  183. 183.

    Sathyapalan T, Shepherd J, Atkin SL, Kilpatrick ES. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study. Diabetes, Obesity and Metabolism. 2013.

    Not in our library10.1111/dom.12074

  184. 184.

    Cummings DM, King DE, Mainous AG. C-reactive protein, antiinflammatory drugs, and quality of life in diabetes. Annals of Pharmacotherapy. 2003;37(11):1593-1597.

    Not in our library10.1345/aph.1d029

  185. 185.

    Rabkin SW, Langer A, Ur E, Calciu CD, Leiter LA. Inflammatory biomarkers CRP, MCP-1, serum amyloid alpha and interleukin-18 in patients with HTN and dyslipidemia: impact of diabetes mellitus on metabolic syndrome and the effect of statin therapy. Hypertension Research. 2013.

    Not in our library10.1038/hr.2012.214

  186. 186.

    Wägner AM, Sánchez-Quesada JL, Benítez S, Bancells C, Ordóñez-Llanos J, Pérez A. Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study. Diabetes Research and Clinical Practice. 2011;93(1):e25-e28.

    Not in our library10.1016/j.diabres.2011.03.009

  187. 187.

    Colbert JD, Stone JA. Statin use and the risk of incident diabetes mellitus: a review of the literature. Canadian Journal of Cardiology. 2012;28(5):581-589.

    Not in our library10.1016/j.cjca.2012.03.021

Cited by papers we hold 9

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.